X4 Pharmaceuticals (X4 Pharmaceuticals) Cash-to-Debt : 1.39 (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is X4 Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. X4 Pharmaceuticals's cash to debt ratio for the quarter that ended in Mar. 2024 was 1.39.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, X4 Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for X4 Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

XFOR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.2 Med: 2.53 Max: 6.28
Current: 1.39

During the past 9 years, X4 Pharmaceuticals's highest Cash to Debt Ratio was 6.28. The lowest was 0.20. And the median was 2.53.

XFOR's Cash-to-Debt is ranked worse than
72.06% of 1539 companies
in the Biotechnology industry
Industry Median: 6.51 vs XFOR: 1.39

X4 Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for X4 Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

X4 Pharmaceuticals Cash-to-Debt Chart

X4 Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

5.51

2.05

2.06

3.17

1.96

X4 Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															2.53	3.83	2.43	1.96	1.39

Competitive Comparison of X4 Pharmaceuticals's Cash-to-Debt

For the Biotechnology subindustry, X4 Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

X4 Pharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, X4 Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where X4 Pharmaceuticals's Cash-to-Debt falls into.

X4 Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

X4 Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	114.216	/	(1.099	+	57.182)
	=	1.96

X4 Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	80.869	/	(1.133	+	57.142)
	=	1.39

X4 Pharmaceuticals (NAS:XFOR) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

X4 Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of X4 Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

X4 Pharmaceuticals (X4 Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » X4 Pharmaceuticals Inc (NAS:XFOR) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

48Q:Germany

Address

61 North Beacon Street, 4th Floor, Boston, MA, USA, 02134

Website

https://www.x4pharma.com

X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream.

Executives

Paula Ragan	director, officer: President and CEO	C/O X4 PHARMACEUTICALS, INC., 955 MASSACHUSETTS AVE., 4TH FLOOR, CAMBRIDGE MA 02139
Mark Baldry	officer: Chief Commercial Officer	C/O AMICUS THERAPEUTICS, 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Arthur Taveras	officer: Chief Scientific Officer	C/O X4 PHARMACEUTICALS, INC., 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON MA 02134
Mary Dibiase	officer: Chief Operating Officer	61 NORTH BEACON STREET, 4TH FLOOR, BOSTON MA 02134
Adam S. Mostafa	officer: See Remarks	C/O X4 PHARMACEUTICALS INC., 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON MA 02134
Keith Woods	director	C/O X4 PHARMACEUTICALS INC., 61 NORTH BEACON STREET 4TH FLOOR, BOSTON MA 02134
Michael S Wyzga	director	RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02139
Christophe Arbet-engels	officer: Chief Medical Officer	C/O MILLENDO THERAPEUTICS, INC., 110 MILLER AVENUE, SUITE 100, ANN ARBOR MI 48104
Murray Stewart	director	C/O NOVELION THERAPEUTICS INC., 1800-510 WEST GEORGIA STREET, VANCOUVER A1 V6B OM3
Craecker Francoise De	director	61 NORTH BEACON STREET, 4TH FLOOR, BOSTON MA 02134
Derek M Meisner	officer: General Counsel	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Diego Cadavid	officer: Chief Medical Officer	C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Alison Frances Lawton	director	39 ROBINSON ROAD, LEXINGTON MA 02420
Renato Skerlj	officer: Chief Scientific Officer	C/O X4 PHARMACEUTICALS, INC., 955 MASSACHUSETTS AVENUE, 4TH FLOOR, CAMBRIGE MA 02139
William Aliski	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949